文献速递儿科与产科急症

肌醇对胎龄小于28周早产儿1型早产儿视网膜病变的影响:一项随机临床试验

Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在胎龄小于28周早产儿中,肌醇治疗至多10周未降低1型早产儿视网膜病变或死亡风险,且全因死亡更高,不支持使用肌醇。

该随机临床试验纳入638例胎龄小于28周早产儿,来自美国18个新生儿重症监护中心,随机接受肌醇40 mg/kg每12小时(初始静脉,喂养后肠道)或安慰剂,至多10周。主要结局为1型早产儿视网膜病变或死亡,肌醇组29% vs 安慰剂组21%(校正风险差7%,95%CI 0%-13%;校正相对风险1.41,95%CI 1.08-1.83,P=0.01)。全因死亡在肌醇组18% vs 安慰剂组11%(校正风险差6%,95%CI 0%-11%;校正相对风险1.66,95%CI 1.14-2.43,P=0.007)。试验因肌醇组死亡率显著更高而提前终止,结论不支持早产儿使用肌醇,但提前终止限制确定性结论。

要点

  • 肌醇组死亡或1型早产儿视网膜病变29% vs 安慰剂组21%,校正相对风险1.41(95%CI 1.08-1.83),P=0.01。
  • 肌醇组全因死亡18% vs 安慰剂组11%,校正相对风险1.66(95%CI 1.14-2.43),P=0.007。
  • 试验因肌醇组死亡率显著更高而提前终止,计划入组1760例,实际入组638例。
  • 常见严重不良事件(至末次给药后7天):坏死性小肠结肠炎肌醇组6% vs 安慰剂组4%,灌注不良或低血压7% vs 4%,脑室内出血10% vs 9%,全身感染16% vs 11%,呼吸窘迫15% vs 13%。
  • 作者结论:这些发现不支持在早产儿中使用肌醇,但试验提前终止限制确定性结论。

适用人群与场景

  • 胎龄小于28周的早产儿,来自美国18个新生儿重症监护中心,入组时间2014年4月17日至2015年9月4日,末次随访2016年2月12日。

处置流程与药物剂量

  • 肌醇40 mg/kg剂量,每12小时给药一次,初始静脉给药,喂养后改为肠道给药,至多10周(肌醇组n=317)。
  • 安慰剂组n=321,给药方案与肌醇组对应。

研究设计与关键结果

  • 随机临床试验,纳入638例胎龄小于28周早产儿(平均胎龄26周,50%男性),来自美国18个新生儿重症监护中心;632例(99%)接受试验药物或安慰剂,589例(92%)有研究结局。
  • 主要结局死亡或1型早产儿视网膜病变:肌醇组29% vs 安慰剂组21%,校正风险差7%(95%CI 0%-13%),校正相对风险1.41(95%CI 1.08-1.83),P=0.01。
  • 全因死亡(55周矫正胎龄前):肌醇组18% vs 安慰剂组11%,校正风险差6%(95%CI 0%-11%),校正相对风险1.66(95%CI 1.14-2.43),P=0.007。
  • 严重不良事件(至末次给药后7天):坏死性小肠结肠炎肌醇组6% vs 安慰剂组4%,灌注不良或低血压7% vs 4%,脑室内出血10% vs 9%,全身感染16% vs 11%,呼吸窘迫15% vs 13%。
  • 试验计划入组1760例,以90%效能检测死亡或1型早产儿视网膜病变绝对降低7%;因肌醇组死亡率显著更高而提前终止。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:试验因肌醇组死亡率显著更高而提前终止,限制确定性结论。

对床旁实践的改变

  • 作者结论:这些发现不支持在早产儿中使用肌醇;但试验提前终止限制确定性结论。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous studies of myo-inositol in preterm infants with respiratory distress found reduced severity of retinopathy of prematurity (ROP) and less frequent ROP, death, and intraventricular hemorrhage. However, no large trials have tested its efficacy or safety.

OBJECTIVE: To test the adverse events and efficacy of myo-inositol to reduce type 1 ROP among infants younger than 28 weeks' gestational age.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial included 638 infants younger than 28 weeks' gestational age enrolled from 18 neonatal intensive care centers throughout the United States from April 17, 2014, to September 4, 2015; final date of follow-up was February 12, 2016. The planned enrollment of 1760 participants would permit detection of an absolute reduction in death or type 1 ROP of 7% with 90% power. The trial was terminated early due to a statistically significantly higher mortality rate in the myo-inositol group.

INTERVENTIONS: A 40-mg/kg dose of myo-inositol was given every 12 hours (initially intravenously, then enterally when feeding; n = 317) or placebo (n = 321) for up to 10 weeks.

MAIN OUTCOMES AND MEASURES: Type 1 ROP or death before determination of ROP outcome was designated as unfavorable. The designated favorable outcome was survival without type 1 ROP.

RESULTS: Among 638 infants (mean, 26 weeks' gestational age; 50% male), 632 (99%) received the trial drug or placebo and 589 (92%) had a study outcome. Death or type 1 ROP occurred more often in the myo-inositol group vs the placebo group (29% vs 21%, respectively; adjusted risk difference, 7% [95% CI, 0%-13%]; adjusted relative risk, 1.41 [95% CI, 1.08-1.83], P = .01). All-cause death before 55 weeks' postmenstrual age occurred in 18% of the myo-inositol group and in 11% of the placebo group (adjusted risk difference, 6% [95% CI, 0%-11%]; adjusted relative risk, 1.66 [95% CI, 1.14-2.43], P = .007). The most common serious adverse events up to 7 days of receiving the ending dose were necrotizing enterocolitis (6% for myo-inositol vs 4% for placebo), poor perfusion or hypotension (7% vs 4%, respectively), intraventricular hemorrhage (10% vs 9%), systemic infection (16% vs 11%), and respiratory distress (15% vs 13%).

CONCLUSIONS AND RELEVANCE: Among premature infants younger than 28 weeks' gestational age, treatment with myo-inositol for up to 10 weeks did not reduce the risk of type 1 ROP or death vs placebo. These findings do not support the use of myo-inositol among premature infants; however, the early termination of the trial limits definitive conclusions.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Phelps DL, Watterberg KL, Nolen TL, et al. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA. 2018. PMID: 30357297. doi:10.1001/jama.2018.14996

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。